Evidence map›Paper›PMID 28130449›Full record

ArticleThe Journal of biological chemistry2017

Interleukin 27 (IL-27) Alleviates Bone Loss in Estrogen-deficient Conditions by Induction of Early Growth Response-2 Gene.

Priyanka Shukla, Mohd Nizam Mansoori, Manisha Kakaji, Manoj Shukla, Sushil Kumar Gupta, Divya Singh

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of biological chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Priyanka ShuklaFrom the Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), Council of Scientific and Industrial Research-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension, Lucknow CDRI-226031 and.
Mohd Nizam MansooriFrom the Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), Council of Scientific and Industrial Research-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension, Lucknow CDRI-226031 and.
Manisha Kakajithe Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow PGI-226014, India.
Manoj Shuklathe Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow PGI-226014, India.
Sushil Kumar Guptathe Department of Endocrinology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow PGI-226014, India.
Divya SinghFrom the Division of Endocrinology and Centre for Research in Anabolic Skeletal Targets in Health and Illness (ASTHI), Council of Scientific and Industrial Research-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension, Lucknow CDRI-226031 and divya_singh@cdri.res.in.
Council of Scientific and Industrial Research · INSanjay Gandhi Post Graduate Institute of Medical Sciences · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A growing understanding of the bone remodeling process suggests that inflammation significantly contributes to the pathogenesis of osteoporosis. T cells and various cytokines contribute majorly to the estrogen deficiency-induced bone loss. Recent studies have identified the IL-12 cytokine family as consisting of pro-inflammatory IL-12 and IL-23 and the anti-inflammatory IL-27 and IL-35 cytokines. IL-27 exerts protective effects in autoimmune diseases like experimental autoimmune encephalomyelitis; however, its role in the pathogenesis of osteoporosis remains to be determined. In this report, we study the effect of IL-27 supplementation on ovariectomized estrogen-deficient mice on various immune and skeletal parameters. IL-27 treatment in ovariectomized mice suppressed Th17 cell differentiation by inhibiting transcription factor RORγt. Supplementation of IL-27 activates Egr-2 to induce IL-10 producing Tr1 cells. IL-27 treatment prevented the loss of trabecular micro-architecture and preserved cortical bone parameters. IL-27 also inhibited osteoblast apoptosis through increased Egr-2 expression, which induces anti-apoptotic factors like MCL-1. IL-27 suppressed osteoclastogenesis in an Egr-2-dependent manner that up-regulates Id2, the repressor of the receptor activator of nuclear factor-κB ligand-mediated osteoclastogenesis. Additionally, these results were corroborated in female osteoporotic subjects where we found decreased serum IL-27 levels along with reduced Egr-2 expression. Our study forms a strong basis for using humanized IL-27 toward the treatment of post-menopausal osteoporosis.

Indexed as

AnimalsAnti-Inflammatory AgentsBone and BonesCells, CulturedEarly Growth Response Protein 2EstrogensFemaleGene DeletionHumansInterleukin-10Interleukin-27MiceMice, Inbred BALB COsteoblastsOsteoclastsOsteoporosis, PostmenopausalAnti-Inflammatory AgentsEarly Growth Response Protein 2Egr2 protein, mouseEstrogensInterleukin-10Interleukin-27RNA, Messengerboneimmunologyimmunosuppressionosteoblastosteoclastosteoporosis

Identifiers

PMID28130449
PMCPMC5377783
OpenAlexW2580868089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.